
Patient dies after receiving faecal transplant
pharmafile | June 17, 2019 | News story | Sales and Marketing | Adverse Event, E.Coli. AMR, FDA, faecal transplant, pharma
A person has died after experiencing an adverse event related to a faecal transplant.
The FDA has warned that two immunocompromised patients developed invasive infections caused by multi drug resistant bacteria, after receiving a faecal transplant.
The patients were infected with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E.coli) after receiving faecal microbiota for transplantation (FMT) from the same donor.
The donor stool and resulting FMT used in these two individuals were not tested for ESBL-producing gram-negative organisms prior to use.
Both patients then developed antibiotic resistant E.Coli infections. One of the patients subsequently died.
FMT is an experimental treatment Clostridium difficile, a bacterial infection which causes severe diarrhoea.
“While we support this area of scientific discovery, it’s important to note that FMT does not come without risk,” said Dr Peter Marks, director of FDA’s Center for Biologics Evaluation and Research.
“We’ve become aware of infections with multi-drug resistant organisms after patients received investigational FMT, including one patient death. We therefore want to alert all health care professionals who administer FMT about this potential serious risk so they can inform their patients.”
Louis Goss
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

FDA grants De Novo authorisation to light-filtering device for migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …





